Steroidal contraceptives: Effect on bone fractures in women

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Lopez, Laureen M ^a   Grimes, D A ^b   Schulz, K F ^b   Curtis, K M ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIANNA; CAPSULAE LEVONORGESTRELI SILASTICUS; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CIPIONATE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETONOGESTREL; FEDRA; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; PLACEBO; STEROID HORMONE; UNCLASSIFIED DRUG;

BIRTH CONTROL; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTRACEPTION; DRUG EFFECT; DRUG IMPLANT; FOLLOW UP; FRACTURE; HEALTH CARE PERSONNEL; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; REVIEW; RISK FACTOR; SUPPLEMENTATION; SYSTEMATIC REVIEW;

EID: 42749098823     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006033.pub2     Document Type: Review

References (50)

1. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Human Reproduction 2006;21:466-70.
2. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstetrics and Gynecology 2004;103:899-906.
3. * Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstetrics and Gynecology 2001;98:576-82.
4. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, Debanne SM. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. American Journal of Obstetrics and Gynecology 2005;192:42-7.
5. Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. Journal of Clinical Endocrinology and Metabolism 2003;88:78-81.
6. Di X, Li Y, Zhang C, Jiang J, Gu S. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception 1999;60:161-6.
7. Endrikat J, Mih E, Dusterberg B, Land K, Gerlinger C, Schmidt W, et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 2004;69:179-87.
8. Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;52:35-9.
9. Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M, et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003;67:355-9.
10. Nappi C, Di Spiezio Sardo A, Greco E, Tommaselli GA, Giordano E, Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bonemineral density. Obstetrics and Gynecology 2005;105:53-60.
11. Paoletti AM, Orru M, Floris S, Mannias M, Vacca AMB, Ajossa S, et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resoprtion in young women. Contraception 2000;61:259-63.
12. von Kesseru E, Etchepareborda JJ, Wikinski R, Beier S. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception 2000;61:317-22.
13. Carr BR, Breslau NA, Peng N, Adams-Huet B, Bradshaw KD, Steinkampf MP. Effect of gonadotropin-releasing hormone agonist andmedroxyprogesterone acetate on calciummetabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial. Fertility and Sterility 2003;80:1216-23.
14. Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR. Longitudinal evaluation of perimenopausal bone loss: Effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 2006;54:176-80.
15. Hauser GA, Girotti M. Effect of placebo instead of a pause in the taking of ovulation inhibitors [Wirking von placebo statt pause bei ovulationshemmern]. Therapeutische Umschau / Revue Thérapeutique 1970;27:666- 70.
16. Pinter B, Kocijancic A, Marc J, Andolsek-Jeras L, Prezelj J. Vitamin D receptor gene polymorphism and bone metabolism during low-dose oral contraceptive use in young women. Contraception 2003;67:33-7.
17. Shuzhi F, Yuanjiao L, Laiying C, et al. The study on the effect of using depo medroxyprogesterone acetate for contraception on bone metabolism. Acta Academiae Medicinae Hubei 2000;21:330-2.
18. Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotrophin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 1993;47:524-44.
19. Teegarden D, Legowski P, Gunther CW, McCabe GP, Peacock M, Lyle RM. Dietary calcium intake protects women consuming oral contraceptives from spine and hip bone loss. Journal of Clinical Endocrinology & Metabolism 2005;90:5127-33.
20. Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, Watts NB. Prior oral contraception and postmenopausal fracture: a Womens' Health Initiative observational cohort study. Fertility and Sterility 2005;84:374-83.
21. Beksinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception 2005;71:170-5.
22. Cleland J, Ali MM. Reproductive consequences of contraceptive failure in 19 developing countries. Obstetrics and Gynecology 2004;104:314- 20.
23. Cromer BA. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Current Opinion in Obstetrics & Gynecology 2003;15:353-7.
24. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
25. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstetrics and Gynecology 1998;92(4 Pt 1):569-73.
26. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Current Opinion in Rheumatology 2005;17:456-61.
27. U.S. Food, Drug Administration. Black box Warning Added Concerning Long-term Use of Depo-Provera Contraceptive Injection. http://www.fda.gov/bbs/ topics/ANSWERS/2004/ANS01325.html (accessed 29 March 2006).
28. Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Archives of Internal Medicine 2004;164:603-14.
29. Grimes DA, Schulz KF. Surrogate end points in clinical research: Hazardous to your health. Obstetrics and Gynecology 2005;105:1114- 8.
30. Hatcher RA. Depo-Provera injections, implants, and progestinonly pills (minipills). In: Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, et al. editor(s). Contraceptive Technology. 18th Edition. New York: Ardent Media, Inc., 2004.
31. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. www.cochrane.dk/cochrane/handbook/ hbook.htm (accessed 1 June 2005).
32. Kaunitz AM. Depo-Provera's black box: time to reconsider?. Contraception 2005;72:165-7.
33. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000;61:77-82.
34. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999;353:1481-4.
35. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000 March 27-29 2000; Vol. 19, issue 1:1-45.
36. Paoletti AM, Orru M, Lello S, Floris S, Ranuzzi F, Etzi R, et al. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception 2004;70:293-8.
37. Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC. Oral contraceptives and bone mineral density: A population-based study. American Journal of Obstetrics and Gynecology 2000;182:265-9.
38. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstetrics and Gynecology 2000;95:736-44.
39. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal of Clinical Investigation 2005;115:3318-25.
40. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine 1990;322:802-9.
41. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. New York: Churchill Livingstone, 1997.
42. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstetrics and Gynecology 1999;93:233-8.
43. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
44. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-5.
45. Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Current Medical Research and Opinion 2005;21:1015- 26.
46. Trussell J. Contraceptive failure in the United States. Contraception 2004;70:89-96.
47. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 1998;57:231-5.
48. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003;68:75-87.
49. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Third Edition. http://www.who.int/reproductivehealth/publications/mec/ index.htm (accessed 05 May 2006).
50. World Health Organization. WHO statement on hormonal contraception and bone health. http://www.who.int/reproductive-health/ family_planning/ bone_health.html (accessed 4 August 2005).